- cafead Mar 09, 2023 at 10:22: AM
via Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.
The company’s stock has been on a steady decline the past five years, settling in around $15 per share as of Thursday. Compared to fellow pharmaceutical big dogs – Pfizer is trading around $40, Novartis double that, and Sanofi at around $47 – there's plenty of room for growth.
article source
The company’s stock has been on a steady decline the past five years, settling in around $15 per share as of Thursday. Compared to fellow pharmaceutical big dogs – Pfizer is trading around $40, Novartis double that, and Sanofi at around $47 – there's plenty of room for growth.
article source